Showing results (1631-1640 of 2,081) with videos related to

Sort By:
Pageof 209
Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectAlain Monnereau, Susan L Slager, Ann Maree Hughes, et al.
World Journal of Clinical Oncology|October 11, 2021
Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single centerLuisa Fernanda Sánchez-Valledor, Thomas M Habermann, Iván Murrieta-Alvarez, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|January 26, 2022
Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasmsHallbera Gudmundsdottir, Jennifer L Tomlinson, Rondell P Graham, et al.
Leukemia|December 8, 2010
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaT E Witzig, C B Reeder, B R LaPlant, et al.
Leukemia & Lymphoma|November 22, 2011
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaRyan A Wilcox, Kay Ristow, Thomas M Habermann, et al.
The New England Journal of Medicine|June 19, 1997
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropeniaL C Hartmann, L K Tschetter, T M Habermann, et al.
Journal of the American College of Surgeons|October 15, 2017
Postoperative Myocardial Infarction in Administrative Data vs Clinical Registry: A Multi-Institutional StudyDavid A Etzioni, Cynthia Lessow, Liliana G Bordeianou, et al.
Cell Host & Microbe|March 17, 2009
HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factorChristine Goffinet, Ina Allespach, Stefanie Homann, et al.
Leukemia & Lymphoma|February 20, 2014
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphomaLuis F Porrata, Kay M Ristow, Thomas M Habermann, et al.
Leukemia|May 21, 2010
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaL F Porrata, K Rsitow, D J Inwards, et al.
Pageof 209